Interferon and its inducers - A never-ending story: "Old" and "new" data in a new perspective

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 1, 2006, Pages

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2 INTERFERON; ALPHA2B INTERFERON; AMPLIGEN; ANTIVIRUS AGENT; BETA INTERFERON; CIDOFOVIR; ENTECAVIR; GAMMA INTERFERON; LAMIVUDINE; NEPLANOCIN A; PEGINTERFERON; POLYACRYLIC ACID; POLYADENYLIC POLYURIDYLIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; POLYMETHACRYLIC ACID; PYRAN COPOLYMER; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; COXSACKIE VIRUS B3; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG STRUCTURE; EBOLA VIRUS; ENCEPHALITIS; FILOVIRUS; HEPATITIS B; HEPATITIS C; HUMAN; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; SARCOMA; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION;

ANTIVIRAL AGENTS; HUMANS; INTERFERON INDUCERS; INTERFERONS; VIRUS DISEASES;

EID: 33748879009     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505351     Document Type: Conference Paper

References (48)

1. Isaacs A, Lindenmann J. Virus interference. I. Interferon. Proc R Soc Lond 1957; 147:258-67.
2. De Somer P, Prinzie A, Denys P Jr, Schonne E. Mechanism of action of interferon. I. Relationship with viral ribonucleic acid. Virology 1962; 16:63-70.
3. Merigan TC. Interferons of mice and men. N Engl J Med 1967; 276:913-20.
4. Merigan TC. Induction of circulating interferon by synthetic anionic polymers of known composition. Nature 1967; 214:416-7.
5. Merigan TC, Regelson W. Interferon induction in man by a synthetic polyanion of defined composition. N Engl J Med 1967; 277:1283-7.
6. De Somer P, De Clercq E, Billiau A, Schonne E, Claesen M. Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro. J Virol 1968; 2:878-85.
7. De Somer P, De Clercq E, Billiau A, Schonne E, Claesen M. Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol 1968; 2:886-93.
8. Merigan TC. Interferon's promise in clinical medicine: fact or fancy? Am J Med 1967; 43:817-21.
9. Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 1967; 58:1004-10.
10. De Clercq E, Merigan TC. Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature 1969; 222:1148-52.
11. De Clercq E, Wells RD, Merigan TC. Increase in antiviral activity of polynucleotides by thermal activation. Nature 1970; 226:364-6.
12. De Clercq E, Wells RD, Grant RC, Merigan TC. Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides. J Mol Biol 1971; 56:83-100.
13. De Clercq E, Eckstein F, Merigan TC. Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 1969; 165:1137-9.
14. Modified RNA aids fight against viral diseases. Chem Eng News 1969; 23 June:17-8.
15. De Clercq E, Nuwer MR, Merigan TC. The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. J Clin Invest 1970; 49:1565-77.
16. De Clercq E, Merigan TC. Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by poly(rI)-poly(rC). Proc Soc Exp Biol Med 1971; 137:590-4.
17. De Clercq E, De Somer P. Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid. Science 1971; 173:260-2.
18. De Clercq E, Edy VG, Torrence PF, Water JA, Witkop B. Antiviral activity of poly(7-deazainosinic acid)-derived complexes in vitro and in vivo. Mol Pharmacol 1976; 12:1045-51.
19. n complex for induction of human interferon. J Mol Biol 1972; 70:567-87.
20. Carter WA, De Clercq E. Viral infection and host defense. Science 1974; 186:1172-8.
21. O'Neill LA. Immunology. After the toll rush. Science 2004; 303:1481-2.
22. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295:517-22.
23. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-96.
24. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464-7.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-7.
26. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-16.
27. De Clercq E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev Anti Infect Ther 2003; 1:21-43.
28. Del Gobbo V, Foli A, Balzarini J, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991; 16:65-75.
29. Calio R, Villani N, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994; 23:77-89.
30. 6-substituted adenines, and 2,6-diaminopurines. Eur J Pharmacol 2003; 475:149-59.
31. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140:346-55.
32. Derynck R, Content J, De Clercq E, et al. Isolation and structure of a human fibroblast interferon gene. Nature 1980; 285:542-7.
33. Derynck R, Remaut E, Saman E, et al. Expression of human fibroblast interferon gene in Escherichia coli. Nature 1980; 287:193-7.
34. PRISMS (Prevention of Relapses and Disability by Interferon β-la Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-la relapsing/remitting multiple sclerosis. Lancet 1998; 352:1498-504.
35. Revel M. Interferon-β in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 2003; 100:49-62.
36. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003; 362:293-4.
37. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus (SCV) infection in macaques. Nat Med 2004; 10:290-3.
38. Harrison SC, Alberts B, Ehrenfeld E, et al. Discovery of antivirals against smallpox. Proc Natl Acad Sci USA 2004; 101:11178-92.
39. De Clercq E, De Somer P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl Microbiol 1968; 16:1314-9.
40. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003; 57:53-60.
41. Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000; 45:135-47.
42. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1):S224-34.
43. De Clercq E, De Somer P. Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus. Life Sci 1968; 7:925-33.
44. De Clercq E, Cools M, Balzarini J, et al. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A and their 5′-nor derivatives. Antimicrob Agents Chemother 1989; 33:1291-7.
45. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2:704-20.
46. Bray M, Raymond JL, Geisbert T, Baker RO. 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res 2002; 55:151-9.
47. Leyssen P, Drosten C, Paning M, et al. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 2003; 47:777-82.
48. 12U)] markedly protects mice against Coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 2004; 48:267-74.